Common mild effects include temporary nausea, bloating, or injection-site redness, resolving quickly
$49 initiation fee due at enrollment and covers initial blood work and laboratory analysis
Glycine Soja (Soybean) Oil, Cera Alba/Beeswax/Cire D'Abeille, Euphorbia Cerifera (Candelilla) Wax/Euphorbia Cerifera Cera/Cire De Candelilla, Ozokerite, Flavor (Aroma), Copernicia Cerifera (Carnauba) Wax/Copernicia Cerifera Cera/Cire De Carnauba, Ethyl Vanillin, Simmondsia Chinensis (Jojoba) Seed Oil, Paraffinum Liquidum/ Mineral Oil/ Huile Minrale, Tocopherol, Propyl Gallate, Aloe Barbadensis (Aloe Vera) Leaf Extract, Gallic Acid, Water/Aqua/Eau, Benzaldehyde, Benzyl Benzoate, Citrus Limon Peel Oil, Geraniol, Limonene, Linalool, Linalyl Acetate, Pinene, Vanillin For the latest information, it is recommended to review the ingredient list printed on the packaging of the product prior to usage or consumption
doi: 10.1039/c8mt00143j 313 SongQLiYCaoZQiangXTanZDengY
Incidence of severe hypoglycemia was 1% b Hypoglycemia was more frequent when RYBELSUS was used in combination with insulin secretagogues (eg, sulfonylurea) or insulin - Patients may require a lower dose of the secretagogue or insulin to reduce the risk of hypoglycemia in this setting A cardiovascular outcomes trial (CVOT) compared RYBELSUS added to standard of care vs placebo added to standard of care Primary endpoint was the time to first occurrence of a 3-part composite outcome of major adverse cardiovascular events (MACE), which included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke The total number of primary component MACE endpoints was 137 (61 [3.8%] with RYBELSUS and 76 [4.8%] with placebo) CV=cardiovascular
